GLP-101:糖尿病教育者对胰高血糖素样肽-1受体激动剂的指导

AADE in practice Pub Date : 2019-08-19 DOI:10.1177/2325160319861453

B. Gillenwater, Andrew N. Wakefield, Jessica S Triboletti, Jasmine D. Gonzalvo, Ashley H. Meredith

{"title":"GLP-101:糖尿病教育者对胰高血糖素样肽-1受体激动剂的指导","authors":"B. Gillenwater, Andrew N. Wakefield, Jessica S Triboletti, Jasmine D. Gonzalvo, Ashley H. Meredith","doi":"10.1177/2325160319861453","DOIUrl":null,"url":null,"abstract":"Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications used to improve glycemic management in people with type 2 diabetes. The first medication in this class, exenatide (Byetta), gained FDA approval in November 2009 and requires twice-daily dosing within 60 minutes prior to morning and evening GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists","PeriodicalId":87215,"journal":{"name":"AADE in practice","volume":"7 1","pages":"32 - 41"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2325160319861453","citationCount":"1","resultStr":"{\"title\":\"GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists\",\"authors\":\"B. Gillenwater, Andrew N. Wakefield, Jessica S Triboletti, Jasmine D. Gonzalvo, Ashley H. Meredith\",\"doi\":\"10.1177/2325160319861453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications used to improve glycemic management in people with type 2 diabetes. The first medication in this class, exenatide (Byetta), gained FDA approval in November 2009 and requires twice-daily dosing within 60 minutes prior to morning and evening GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists\",\"PeriodicalId\":87215,\"journal\":{\"name\":\"AADE in practice\",\"volume\":\"7 1\",\"pages\":\"32 - 41\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2325160319861453\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AADE in practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2325160319861453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AADE in practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2325160319861453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

胰高血糖素样肽-1（GLP-1）受体激动剂是一类用于改善2型糖尿病患者血糖管理的注射药物。这类药物中的第一种，艾塞那肽（Byetta），于2009年11月获得美国食品药品监督管理局批准，需要在早晚GLP-101前60分钟内每天两次给药：糖尿病教育者指南胰高血糖素样肽-1受体激动剂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications used to improve glycemic management in people with type 2 diabetes. The first medication in this class, exenatide (Byetta), gained FDA approval in November 2009 and requires twice-daily dosing within 60 minutes prior to morning and evening GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

AADE in practice

自引率

0.00%

发文量